Supplementary Online Content


**eFigure 1.** Days of Therapy (DOT) / 1,000 Patient Days by Antibiotic Class for Critical Care and non-Critical Care locations, 2006-2012 Truven MarketScan Hospital Drug Database

**eFigure 2.** Proportion of Mean Days of Therapy / 1,000 Patient Days by Antibiotic Class over Time from 2006-2012, Truven MarketScan Hospital Drug Database

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1: Days of Therapy (DOT) / 1,000 Patient Days by Antibiotic Class for Critical Care and non-Critical Care locations, 2006-2012 Truven MarketScan Hospital Drug Database

eFigure 2: Proportion of Mean Days of Therapy / 1,000 Patient Days by Antibiotic Class over Time from 2006-2012, Truven MarketScan Hospital Drug Database
eFigure 1: Days of Therapy (DOT) / 1,000 Patient Days by Antibiotic Class for Critical Care and non-Critical Care locations, 2006-2012 Truven MarketScan Hospital Drug Database
All Aminoglycosides
1st and 2nd Gen Cephalosporins
Penicillins
Carbapenems
Beta-lactam/Beta-lactamase inhibitor combinations
Sulfa
Glycopeptide
Macrolides
Fluoroquinolones
Lincosamide
3rd and 4th Gen Cephalosporins
1st and 2nd Gen Cephalosporins
Aminoglycosides
Metronidazole
Other
Tetracyclines
DOT / 1,000 Patient Days
© 2016 American Medical Association. All rights reserved.
eFigure 2: Proportion of Mean Days of Therapy / 1,000 Patient Days by Antibiotic Class over Time from 2006-2012, Truven MarketScan Hospital Drug Database